Ardent Health stock
ARDTNYSEArdent Health Inc., HealthcareISIN US03980N1072
60Score 60 out of 100, Neutral
Price and trend
77 / 100
Price history
+29% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 77% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 86).
The price is at its 52-week high. Largest decline in 2 years: 61% (October 2024 to June 2026).
Chart figures for advanced users
- SMA 50$11.87
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$10.26
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)86
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.83
- The lowest closing price of the last twelve months.
- Resistance$18.19
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Ardent Health Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $2.56B, is number 26 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $6.32B (up 6% year on year) and earnings of $135.81M (down 35.4%).
- For fiscal 2026, analysts expect on average revenue of $6.48B (up 2.4%) and adjusted earnings per share of $1.02 (down 38.2%).
Show more
- MEQIRI Score 60 out of 100 (Neutral): rank 274 of 714 in Healthcare, median 53.
- The P/E is 17.6 (Medical (Care Facilities) median 19.4, own median of recent years 10).
- Our model puts fair value at $21.88, with the price 17% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 192% of earnings over the last 12 months.Fundamentals 62
Weaknesses
- Volatile share priceVolatility 60% a year over the last 12 months.Stability 55
Its standout strengths are momentum and technical analysis, while capital allocation and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- high price swings
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $15.63 and expensive above $36.47 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $23.79 (cash-flow model) and $19.98 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $19.78, at 7.8% it would be $25.04.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 2% on the twelve months before. Revenue has grown strongly since 2015, at around 15% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 98%, operating 5%, net 2%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Mar 2027in 111 days
- Last reported
- 4 Nov 2026EPS reported $0.31 (expected $0.23)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 6.8% since 15 Oct 2026.
- Earnings per share
- $1.02+6.8%
- Revenue
- $6.48B+0.2%
- Earnings per share
- $1.23+5.3%
- Revenue
- $6.69B−0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +7.8%2026 revenue and adjusted EBITDA guidance maintained despite lower volumes (about $25 million headwind); savings target raised to over $70 million.
“We have increased our 2026 savings target twice from $40 million originally to the $55 million target established in the fourth quarter of 2025 earnings call to now over $70 million expected to be realized this year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $186,400 in total.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Ardent Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 60
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Surgery PartnersSGRY $3.49B53
- National HealthCareNHC $3.3B68
- Guardian Pharmacy ServicesGRDN $3.16B77
- Aveanna Healthcare HoldingsAVAH $2.86B63
- Pediatrix Medical GroupMD $2.46B70
- Addus HomeCareADUS $2.34B71
- Brookdale Senior LivingBKD $2.2B24
- Agilon HealthAGL $1.93B48
ETFs that hold Ardent Health
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.03% | 0.39% | €1.47B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 8 Aug 2025)
- Valuation signal Fairly valued since 7 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.